The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study

FGF21 Increases Cholesterol Efflux by Upregulating ABCA1 Through the ERK1/2–PPARγ–LXRα Pathway in THP1 Macrophage-Derived Foam Cells

(2014) Xiao-Long Lin et al.   DNA AND CELL BIOLOGY

Serum Fibroblast Growth Factor-21 Levels Are Associated With Carotid Atherosclerosis Independent of Established Cardiovascular Risk Factors

(2013) Wing Sun Chow et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Prognostic value of multiple emerging biomarkers in cardiovascular risk prediction in patients with stable cardiovascular disease

(2013) Namanjeet Ahluwalia et al.   ATHEROSCLEROSIS

Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease

(2013) Yun Shen et al.   Cardiovascular Diabetology

The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes

(2013) Gregory Gaich et al.   Cell Metabolism

Serum levels of fibroblast growth factor-21 are increased in chronic and acute renal dysfunction

(2013) Janka Hindricks et al.   CLINICAL ENDOCRINOLOGY

Serum levels of the adipokine fibroblast growth factor-21 are increased in preeclampsia

(2013) Holger Stepan et al.   CYTOKINE

Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions

(2013) K. M. Habegger et al.   DIABETES

Serum fibroblast growth factor 21 is predictive of combined cardiovascular morbidity and mortality in patients with type 2 diabetes at a relatively short-term follow-up

(2013) M. Lenart-Lipińska et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Fibroblast growth factor 21 protects against cardiac hypertrophy in mice

(2013) A. Planavila et al.   Nature Communications

Cardioprotective proteins upregulated in the liver in response to experimental myocardial ischemia

(2012) Shu Q. Liu et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Cholesterol Metabolism Altered and FGF21 Levels High After Pediatric Liver Transplantation Despite Normal Serum Lipids

(2012) S. Kosola et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Fibroblast Growth Factor 21 as an emerging metabolic regulator: clinical perspectives

(2012) Y. C. Woo et al.   CLINICAL ENDOCRINOLOGY

Serum FGF21 concentration is associated with hypertriglyceridaemia, hyperinsulinaemia and pericardial fat accumulation, independently of obesity, but not with current coronary artery status

(2012) Yenna Lee et al.   CLINICAL ENDOCRINOLOGY

Long-Term Fenofibrate Therapy Increases Fibroblast Growth Factor 21 and Retinol-Binding Protein 4 in Subjects with Type 2 Diabetes

(2012) Kwok Leung Ong et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Fibroblast growth factor-21 serum concentrations are associated with metabolic and hepatic markers in humans

(2012) Susan Kralisch et al.   JOURNAL OF ENDOCRINOLOGY

Treating Diabetes and Obesity with an FGF21-Mimetic Antibody Activating the  Klotho/FGFR1c Receptor Complex

(2012) I. N. Foltz et al.   Science Translational Medicine

Do novel biomarkers add to existing scores of total cardiovascular risk?

(2012) Guy De Backer et al.   European Journal of Preventive Cardiology

FGF21 Analogs of Sustained Action Enabled by Orthogonal Biosynthesis Demonstrate Enhanced Antidiabetic Pharmacology in Rodents

(2011) J. Mu et al.   DIABETES

High Plasma Level of Fibroblast Growth Factor 21 Is an Independent Predictor of Type 2 Diabetes: A 5.4-year population-based prospective study in Chinese subjects

(2011) C. Chen et al.   DIABETES CARE

Circulating FGF21 Levels Are Progressively Increased from the Early to End Stages of Chronic Kidney Diseases and Are Associated with Renal Function in Chinese

(2011) Zhuofeng Lin et al.   PLoS One

Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride

(2010) Huating Li et al.   JOURNAL OF HEPATOLOGY

Serum Levels of FGF-21 Are Increased in Coronary Heart Disease Patients and Are Independently Associated with Adverse Lipid Profile

(2010) Zhuofeng Lin et al.   PLoS One

Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers

(2010) Michael J. Pencina et al.   STATISTICS IN MEDICINE

Relationships of HDL Cholesterol, ApoA-I, and ApoA-II With Homocysteine and Creatinine in Patients With Type 2 Diabetes Treated With Fenofibrate

(2009) Marja-Riitta Taskinen et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

(2009) D. C. Burgess et al.   EUROPEAN HEART JOURNAL

Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial

(2009) Kushwin Rajamani et al.   LANCET

Serum FGF21 Levels Are Increased in Obesity and Are Independently Associated With the Metabolic Syndrome in Humans

(2008) X. Zhang et al.   DIABETES